ATE95193T1 - Cyclosporine und deren benutzung als arzneimittel. - Google Patents

Cyclosporine und deren benutzung als arzneimittel.

Info

Publication number
ATE95193T1
ATE95193T1 AT88810403T AT88810403T ATE95193T1 AT E95193 T1 ATE95193 T1 AT E95193T1 AT 88810403 T AT88810403 T AT 88810403T AT 88810403 T AT88810403 T AT 88810403T AT E95193 T1 ATE95193 T1 AT E95193T1
Authority
AT
Austria
Prior art keywords
residue
cyclosporins
mebmt
dihydro
substituted
Prior art date
Application number
AT88810403T
Other languages
English (en)
Inventor
Pietro Bollinger
Johann Jakob Boelsterli
Jean-Francois Borel
Manfred Krieger
Trevor Glyn Payne
Rene P Traber
Roland Wenger
Original Assignee
Sandoz Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878714119A external-priority patent/GB8714119D0/en
Priority claimed from GB878714115A external-priority patent/GB8714115D0/en
Priority claimed from GB878714125A external-priority patent/GB8714125D0/en
Priority claimed from GB878714100A external-priority patent/GB8714100D0/en
Priority claimed from GB878714098A external-priority patent/GB8714098D0/en
Priority claimed from GB878714090A external-priority patent/GB8714090D0/en
Priority claimed from GB878714118A external-priority patent/GB8714118D0/en
Priority claimed from GB878714093A external-priority patent/GB8714093D0/en
Application filed by Sandoz Ag filed Critical Sandoz Ag
Application granted granted Critical
Publication of ATE95193T1 publication Critical patent/ATE95193T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • C07K7/645—Cyclosporins; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT88810403T 1987-06-17 1988-06-14 Cyclosporine und deren benutzung als arzneimittel. ATE95193T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
GB878714119A GB8714119D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714115A GB8714115D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714125A GB8714125D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714100A GB8714100D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714098A GB8714098D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714090A GB8714090D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714118A GB8714118D0 (en) 1987-06-17 1987-06-17 Organic compounds
GB878714093A GB8714093D0 (en) 1987-06-17 1987-06-17 Organic compounds
EP88810403A EP0296122B1 (de) 1987-06-17 1988-06-14 Cyclosporine und deren Benutzung als Arzneimittel

Publications (1)

Publication Number Publication Date
ATE95193T1 true ATE95193T1 (de) 1993-10-15

Family

ID=27571252

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88810403T ATE95193T1 (de) 1987-06-17 1988-06-14 Cyclosporine und deren benutzung als arzneimittel.

Country Status (21)

Country Link
US (1) US5525590A (de)
EP (1) EP0296122B1 (de)
JP (2) JPH0832724B2 (de)
KR (1) KR970010927B1 (de)
AT (1) ATE95193T1 (de)
AU (1) AU614086B2 (de)
CA (1) CA1338728C (de)
CY (1) CY1939A (de)
CZ (1) CZ411791A3 (de)
DE (1) DE3884470T2 (de)
DK (1) DK173873B1 (de)
ES (1) ES2059558T3 (de)
HK (1) HK152796A (de)
HU (1) HU211678A9 (de)
IE (1) IE62482B1 (de)
IL (1) IL86751A (de)
MY (1) MY103582A (de)
NZ (1) NZ225041A (de)
PT (1) PT87745B (de)
SA (1) SA97170746A (de)
SK (1) SK411791A3 (de)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0283801A3 (de) * 1987-03-27 1990-05-30 Abbott Laboratories Fluoreszenz-Polarisations-Test für Cyclosporin A und Metaboliten und verwandte Immunogene und Antikörper
US5236899A (en) * 1987-11-16 1993-08-17 Merck & Co., Inc. 6-position cyclosporin a analogs as modifiers of cytotoxic drug resistance
US6007840A (en) * 1988-09-16 1999-12-28 Novartis Ag Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) * 1988-09-16 1998-08-17 장 크라메르, 한스 루돌프 하우스 사이클로스포린을 함유하는 약학조성물
BE1003009A5 (fr) * 1989-02-09 1991-10-22 Sandoz Sa Nouvelles compositions pharmaceutiques a base de cyclosporines.
US5540931A (en) * 1989-03-03 1996-07-30 Charles W. Hewitt Methods for inducing site-specific immunosuppression and compositions of site specific immunosuppressants
GB8916901D0 (en) * 1989-07-24 1989-09-06 Sandoz Ltd Improvements in or relating to organic compounds
US5122511A (en) * 1990-02-27 1992-06-16 Merck & Co., Inc. Immunosuppressive cyclosporin analogs with modified amino acids at position-8
US6262022B1 (en) 1992-06-25 2001-07-17 Novartis Ag Pharmaceutical compositions containing cyclosporin as the active agent
GB9204466D0 (en) * 1992-03-02 1992-04-15 Sandoz Ltd Improvements in or relating to organic compounds
GB9208712D0 (en) * 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
SG45449A1 (en) * 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
CZ278863B6 (en) * 1992-09-07 1994-07-13 Galena Medicinal preparations with n-methylated cyclic undecapeptides
DK0589843T3 (da) 1992-09-25 2002-04-02 Novartis Ag Cyclosporinholdige farmaceutiske præparater
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
US6187547B1 (en) 1993-09-08 2001-02-13 Novartis Ag Assay kit
GB9318612D0 (en) * 1993-09-08 1993-10-27 Sandoz Ltd An assay
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
ES2177652T3 (es) 1994-11-03 2002-12-16 Novartis Ag Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
GR1002687B (el) * 1995-04-17 1997-05-06 Novartis Ag (Novartis Sa) (Novartis Inc.) Διαδικασια παραγωγης.
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) * 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
KR20050084502A (ko) 1997-01-30 2005-08-26 노파르티스 아게 오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
AU750245B2 (en) * 1997-10-08 2002-07-11 Aurinia Phamaceuticals Inc. Deuterated cyclosporine analogs and their use as immunomodulating agents
US20030220234A1 (en) * 1998-11-02 2003-11-27 Selvaraj Naicker Deuterated cyclosporine analogs and their use as immunodulating agents
AU748334B2 (en) 1997-10-16 2002-05-30 Board Of Regents, The University Of Texas System Models and treatments for cardiac hypertrophy in relation with NF-AT3 function
PT1091975E (pt) 1998-07-01 2006-05-31 Debiopharm Sa Nova ciclosporina com um perfil de actividade melhorado
DK1154759T3 (da) 1998-12-30 2008-12-08 Dexcel Ltd Dispergerbart koncentrat til indgift af cyclosporin
US6255280B1 (en) * 1999-04-08 2001-07-03 University Of Kentucky Research Foundation Protection against traumatic brain injury
US7732404B2 (en) 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
US6784156B2 (en) 2001-03-05 2004-08-31 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of respiratory diseases
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
US20030087813A1 (en) * 2001-10-12 2003-05-08 Or Yat Sun Cyclosporin analogs for the treatment of lung diseases
US6809077B2 (en) * 2001-10-12 2004-10-26 Enanta Pharmaceuticals, Inc. Cyclosporin analogs for the treatment of autoimmune diseases
ES2310604T3 (es) * 2001-10-19 2009-01-16 Isotechnika, Inc. Mezclas de analogos de ciclosporinas y su uso como agentes inmunomoduladores.
EP2116228A1 (de) 2001-10-19 2009-11-11 Isotechnika Inc. Neuartige Cyclosporinanalog-Mikroemulsionspräkonzentrate
WO2003033526A2 (en) * 2001-10-19 2003-04-24 Isotechnika Inc. Synthesis of cyclosporin analogs
US7012065B2 (en) 2003-02-07 2006-03-14 Enanta Pharmaceuticals, Inc. Cyclosporins for the treatment of immune disorders
JP2006524232A (ja) * 2003-03-17 2006-10-26 アルバニー モレキュラー リサーチ インコーポレーティッド 新規サイクロスポリン
TW200505946A (en) * 2003-04-08 2005-02-16 Hoffmann La Roche Process for preparation of cyclosporin a analog
WO2005097116A1 (en) * 2004-04-08 2005-10-20 Applied Research Systems Ars Holding N.V. Composition comprising a jnk inhibitor and cyclosporin
US20060014677A1 (en) * 2004-07-19 2006-01-19 Isotechnika International Inc. Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds
EP1804823A4 (de) * 2004-09-29 2010-06-09 Amr Technology Inc Neue cyclosporin-analoga und ihre pharmazeutischen anwendungen
JP2008514701A (ja) * 2004-09-29 2008-05-08 エーエムアール テクノロジー インコーポレイテッド シクロスポリンアルキン類似体およびそれらの薬学的使用
US7361636B2 (en) * 2004-10-06 2008-04-22 Amr Technology, Inc. Cyclosporin alkynes and their utility as pharmaceutical agents
CA2592343A1 (en) * 2004-12-17 2006-06-22 Isotechnika Inc. Metabolites of cyclosporin analogs
US7696165B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne analogues for preventing or treating viral-induced disorders
US7696166B2 (en) * 2006-03-28 2010-04-13 Albany Molecular Research, Inc. Use of cyclosporin alkyne/alkene analogues for preventing or treating viral-induced disorders
WO2008036244A1 (en) * 2006-09-18 2008-03-27 The Burham Institute For Medical Research Use of cyclosporin a to sensitize resistant cancer cells to death receptor ligands
JP5801534B2 (ja) * 2007-01-04 2015-10-28 デビオファーム インターナショナル ソシエテ アノニム ウールリッヒ型先天筋ジストロフィーの処置のための、非免疫抑制性シクロスポリン
TW200932240A (en) 2007-10-25 2009-08-01 Astellas Pharma Inc Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production
BRPI0911709A2 (pt) * 2008-07-30 2017-06-20 Isotechnika Labs Inc composto, processo para a produção de um composto, composição farmacêutica e método de tratar uma doença mediada a ciclofilina em um mamífero
JP6265583B2 (ja) 2008-10-17 2018-01-24 ウィスコンシン アルムニ リサーチ ファンデイション 生理活性アルファベータペプチドを作製する方法
EP2376524B1 (de) * 2008-12-31 2017-03-15 Cypralis Limited Derivate von cyclosporin a
SG173180A1 (en) * 2009-01-30 2011-09-29 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c infection
US8481483B2 (en) * 2009-02-19 2013-07-09 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8685917B2 (en) * 2009-07-09 2014-04-01 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
US8349312B2 (en) * 2009-07-09 2013-01-08 Enanta Pharmaceuticals, Inc. Proline substituted cyclosporin analogues
US8367053B2 (en) * 2009-07-09 2013-02-05 Enanta Pharmaceuticals, Inc. Cyclosporin analogues
DE102009037551A1 (de) * 2009-08-17 2011-02-24 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Cyclosporinderivate
US8623814B2 (en) * 2010-02-23 2014-01-07 Enanta Pharmaceuticals, Inc. Antiviral agents
WO2011141891A1 (en) 2010-05-12 2011-11-17 Debio Recherche Pharmaceutique S.A. Use of cycloundecadepsipeptide compounds
JP6144627B2 (ja) 2010-12-15 2017-06-07 コントラヴィア ファーマシューティカルズ、インク． アミノ酸１および３で修飾されたシクロスポリン類似体分子
WO2012145427A1 (en) 2011-04-18 2012-10-26 The Trustees Of Columbia University In The City Of New York Methods to treat cancer using cyclosporine and cyclosporine derivatives
WO2014049540A2 (en) 2012-09-29 2014-04-03 Novartis Ag Cyclic peptides and use as medicines
US8906853B2 (en) 2012-11-28 2014-12-09 Enanta Pharmaceuticals, Inc. [N-Me-4-hydroxyleucine]-9-cyclosporin analogues for treatment and prevention of hepatitis C infection
SG11201601274QA (en) 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
WO2016073480A1 (en) 2014-11-03 2016-05-12 Enanta Pharmaceuticals, Inc. Novel cyclosporin analogues for preventing or treating hepatitis c infection
EP3233918A1 (de) 2014-12-19 2017-10-25 Novartis AG Kombinationstherapien
JO3746B1 (ar) 2015-03-10 2021-01-31 Aduro Biotech Inc تركيبات وطرق لتنشيط الإشارات المعتمدة على "منبه أو تحفيز جين انترفيرون"
EP4378957A3 (de) 2015-07-29 2024-08-07 Novartis AG Kombinationstherapien mit antikörpermolekülen gegen pd-1
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
CA2996064C (en) 2015-08-18 2024-02-13 Novation Pharmaceuticals Inc. Benzopyran derivatives and uses thereof
KR20250099459A (ko) 2015-11-03 2025-07-01 얀센 바이오테크 인코포레이티드 Pd-1과 특이적으로 결합하는 항체 및 그의 용도
EP3389712B1 (de) 2015-12-17 2024-04-10 Novartis AG Antikörpermoleküle gegen pd-1 und verwendungen davon
EP3507367A4 (de) 2016-07-05 2020-03-25 Aduro BioTech, Inc. Cyclisches dinukleotidverbindungen mit eingeschlossenen nukleinsäuren und verwendungen davon
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US12398209B2 (en) 2018-01-22 2025-08-26 Janssen Biotech, Inc. Methods of treating cancers with antagonistic anti-PD-1 antibodies
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
WO2020014652A1 (en) * 2018-07-13 2020-01-16 New York University Peptoid-peptide macrocycles, pharmaceutical compositions and methods of using the same
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
CN114208781B (zh) * 2022-01-20 2022-12-20 河南农业大学 一种抑制草地贪夜蛾龄期的方法及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4210581A (en) * 1975-11-04 1980-07-01 Sandoz Ltd. Organic compounds
CH614931A5 (de) * 1975-11-04 1979-12-28 Sandoz Ag
EP0034567B1 (de) * 1980-02-14 1984-11-07 Sandoz Ag Verfahren zur Totalsynthese von Cyclosporinen und neue Cyclosporine
CH667274A5 (de) * 1984-03-23 1988-09-30 Sandoz Ag Cyclosporine, ihre herstellung und diese enthaltende pharmazeutische zusammensetzungen.
GB8407618D0 (en) * 1984-03-23 1984-05-02 Sandoz Ltd Organic compounds
EP0194972B1 (de) * 1985-03-11 1992-07-29 Sandoz Ag Cyclosporine
US4798823A (en) * 1987-06-03 1989-01-17 Merck & Co., Inc. New cyclosporin analogs with modified "C-9 amino acids"

Also Published As

Publication number Publication date
DK326588A (da) 1988-12-18
DK326588D0 (da) 1988-06-15
EP0296122A3 (en) 1990-06-20
MY103582A (en) 1993-08-28
ES2059558T3 (es) 1994-11-16
IL86751A0 (en) 1988-11-30
US5525590A (en) 1996-06-11
IE881807L (en) 1988-12-17
JPH0832724B2 (ja) 1996-03-29
JPS6445396A (en) 1989-02-17
HU211678A9 (en) 1995-12-28
SK411791A3 (en) 1995-07-11
CY1939A (en) 1997-05-16
CA1338728C (en) 1996-11-19
AU1767988A (en) 1988-12-22
SA97170746A (ar) 2005-12-03
AU614086B2 (en) 1991-08-22
PT87745A (pt) 1988-07-01
EP0296122B1 (de) 1993-09-29
PT87745B (pt) 1992-10-30
IE62482B1 (en) 1995-02-08
JP2772372B2 (ja) 1998-07-02
JPH0848696A (ja) 1996-02-20
IL86751A (en) 1994-02-27
EP0296122A2 (de) 1988-12-21
DE3884470T2 (de) 1994-03-10
NZ225041A (en) 1991-03-26
CZ411791A3 (en) 1993-02-17
DK173873B1 (da) 2002-01-21
KR970010927B1 (ko) 1997-07-02
KR890000519A (ko) 1989-03-15
DE3884470D1 (de) 1993-11-04
HK152796A (en) 1996-08-16

Similar Documents

Publication Publication Date Title
DE3884470D1 (de) Cyclosporine und deren benutzung als arzneimittel.
ATE72988T1 (de) Fettsaeure-zusammensetzungen.
DK0641342T3 (da) Antivirale 2-ethyl-1H-imidazo(4,5-c)quinolin-4-aminer
NO306677B1 (no) Heterosykliske forbindelser, farmasöytiske preparater og anvendelse av en slik forbindelse til fremstilling av et medikament
ATE108794T1 (de) Therapeutische nucleoside und deren herstellung.
MX9205046A (es) 1h-imidazo-(4,5-c)quinolin-4-aminas 1-substituidas
IL89835A0 (en) Substituted azetidinones,their preparation and pharmaceutical compositions containing them
DE69713151D1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE3887014D1 (de) Nukleoside, ihre Herstellung und pharmazeutische Zusammenstellungen.
CA2201477A1 (en) New pyrimidone derivatives with antifungal activity
DE3875769D1 (de) Therapeutische nukleoside.
GB9214053D0 (en) Heterocyclic amides
EP0334853A4 (de) Weiche steroide mit anti-entzündungswirkung.
FI945696A0 (fi) Laktaamidipeptidejä, joilla on HLE:a inhiboiva aktiivisuus
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
MY103593A (en) Bicyclic compounds, their use as pharmaceuticals, their preparation, and intermediates useful in their preparation
FR2701952B1 (fr) Nouveaux dérivés cyclopeptidiques de l'angiopeptine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
NO174963C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive 8-fluorantracyklinglucosider
DE3854158D1 (de) Nucleosid-analoge.
MY103900A (en) 6-substituted 2'', 3''-dideoxynucleosides and pharmaceutical compositions

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time